CSPIA
NVAX icon

Cary Street Partners Investment Advisory’s Novavax NVAX Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-35
Closed -$253 – 1412
2023
Q3 		$253 Hold
35
– – ﹤0.01% 1819
2023
Q2 		$260 Hold
35
– – ﹤0.01% 1709
2023
Q1 		$243 Sell
35
-5
-13% -$46 ﹤0.01% 1639
2022
Q4 		$411 Buy
+40
New +$706 ﹤0.01% 1628

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cary Street Partners Investment Advisory's NVAX Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Novavax (NVAX) in Q4 2023, closing a stake of 35 shares — an estimated $253 sold.

Cary Street Partners Investment Advisory first reported a position in NVAX in Q4 2022 and held it in 4 quarters. The position peaked at $411 in Q4 2022. 200 funds tracked by Wall St. Rank hold NVAX as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Novavax position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 35 Novavax shares in Q4 2023, an estimated $253.
  • Cary Street Partners Investment Advisory first reported a position in Novavax in Q4 2022 and held it in 4 quarters.
  • Cary Street Partners Investment Advisory's Novavax position peaked at $411 in Q4 2022.
  • 200 funds tracked by Wall St. Rank held Novavax as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.